Site icon pigpork News, swine information

Philippines shifts animal health oversight to agri agencies

Escrito por: porciNews Asia

Photo credit: Philippine Department of Agriculture

Regulatory oversight over animal health and local dairy products in the Philippines has shifted to the Department of Agriculture (DA) after the Animal Industry Development and Competitiveness Act took effect on October 28, 2025.

The law mandates the transfer of oversight from the Food and Drug Administration (FDA) to the Bureau of Animal Industry (BAI) and the National Dairy Authority (NDA).

BAI  takes charge of veterinary oversight

The Bureau of Animal Industry (BAI) now holds exclusive jurisdiction over veterinary drugs, biologics, vaccines, and related animal health products. Its authority extends to livestock, poultry, dairy, and companion animals.

Covered establishments include manufacturers, distributors, and sellers of veterinary products. The BAI now manages licensing, product registration, inspections, surveillance, enforcement, and post-market monitoring.

The BAI also oversees:

Revalidation and compliance with post-approval commitments attached to FDA authorizations, such as Certificates of Product Registration, must be submitted directly to the BAI. Failure to comply will result in appropriate regulatory actions.

NDA strengthens dairy industry regulation

The National Dairy Authority (NDA) assumes responsibility for local dairy products and activities. It serves as the certifying agency for the dairy industry chain, regulating micro, small, medium, and commercial dairy processing plants.

Products under NDA oversight include:

Transition deadlines and compliance

The law sets clear statutory deadlines:

Pending FDA applications without payment will no longer be accepted.

What’s up next for stakeholders

Affected establishments must comply with DA-BAI and NDA regulations. Market authorization holders are urged to monitor updates and attend consultations during the transition. The advisory clarifies jurisdictional boundaries while preserving the statutory mandates of the FDA and DA agencies.

Exit mobile version